Consortium Including ElsaLys Biotech and Novadiscovery Awarded €3.35 Million by Bpifrance to Advance Inolimomab in Graft-versus-host Disease

Lyon, France, Jan. 19 (Korea Bizwire) – The Silikotac Program consortium, consisting of ElsaLys Biotech, Novadiscovery (“NOVA”) and two expert academic teams from Hôpital St Louis (Paris) and Hôpital Henri Mondor (Paris), has been awarded €3.35 million in non-dilutive funding by Bpifrance to support development of inolimomab in graft-versus-host disease (GvHD), the main complication that [...]